STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 160502

TO: Shailendra Kumar **Location: 5c03 / 5c18** **Friday, August 05, 2005** **Art Unit: 1621** **Phone: 571-272-0640** **Serial Number: 10 / 828601**	**From: Jan Delaval** **Location: Biotech-Chem Library** **Remsen 1a51** **Phone: 571-272-2504** **jan.delaval@uspto.gov**

Search Notes

Ian please

Access DB# 160502

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 7/26/05
Art Unit: 1621 Phone Number #) 2-0640 Serial Number: 10/828601
Mail Box and Bldg/Room Location: REM 5C03 5C18 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: Lidocaine analogs and methods of making and using th

Inventors (please provide full names): Victor P. Chu et. al

Earliest Priority Filing Date: 4/22/04

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



Z is nucleophilic group and optionally a protecting gr
L is linker
R1 - R5 are H, protecting group, or alkyl
R1 & R3 together may form ring

****

STAFF USE ONLY

Searcher: [signature]
Searcher Phone #: 22504
Searcher Location:
Date Searcher Picked Up: 8/5/05
Date Completed: 8/9/05
Searcher Prep & Review Time:
Clerical Prep Time: 15
Online Time: T35

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#) ✓
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN ✓
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 AUG 2005  HIGHEST RN 858414-27-4
DICTIONARY FILE UPDATES:   4 AUG 2005  HIGHEST RN 858414-27-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l20
L13             STR
```




```
VAR G1=4/5/6
NODE ATTRIBUTES:
NSPEC   IS RC     AT  11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
```

NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L15 5958 SEA FILE=REGISTRY SSS FUL L13
L18 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 11
CONNECT IS E1 RC AT 12
CONNECT IS E1 RC AT 14
CONNECT IS E1 RC AT 15
CONNECT IS E1 RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L20 18 SEA FILE=REGISTRY SUB=L15 SSS FUL L18

100.0% PROCESSED 3102 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

=> d his

(FILE 'HCAPLUS' ENTERED AT 09:28:10 ON 05 AUG 2005)
DEL HIS
E CHU V/AU
L1 173 S E3,E6,E26,E32,E33
E TENG Z/AU
L2 22 S E3-E5 OR TENG ZHU?/AU
E LEWISCH S/AU
L3 5 S E4
E EDWARDS R/AU
L4 306 S E3,E20-E22
E EDWARDS RON/AU
L5 4 S E3,E6,E13
L6 510 S L1-L5
L7 0 S L6 AND ?LIDOCAIN?
L8 8 S L6 AND BENZ?/SC,SX
L9 0 S L1 AND L2-L5
L10 0 S L2 AND L3-L5
L11 0 S L3 AND L4,L5
L12 0 S L4 AND L5

```
     FILE 'REGISTRY' ENTERED AT 09:30:46 ON 05 AUG 2005
L13             STR
L14           50 S L13
L15         5958 S L13 FUL
                SAV L15 KUMAR828/A
L16            0 S L15 AND C21H37N5O2
L17            0 S L15 AND C24H41N5O5
L18             STR L13
L19            2 S L18 SAM SUB=L15
L20           18 S L18 FUL SUB=L15
                SAV L20 KUMAR828A/A
L21          332 S L15 AND PMS/CI
L22            0 S L21 AND (LATEX OR STARCH)
L23            1 S STARCH/CN
L24            0 S 9005-25-8/CRN AND L15
L25           16 S L15 AND OC2/ES

     FILE 'HCAPLUS' ENTERED AT 09:47:08 ON 05 AUG 2005
L26         2747 S L15
L27            0 S L6 AND L26
L28            0 S L26 AND (DADE? OR BEHRING? OR DEUTSCHE BANK?)/PA,CS
L29            6 S L26 AND ?LIDOCAIN?

     FILE 'REGISTRY' ENTERED AT 09:49:05 ON 05 AUG 2005
L30            1 S LIDOCAINE/CN
L31          248 S 137-58-6/CRN

     FILE 'HCAPLUS' ENTERED AT 09:49:28 ON 05 AUG 2005
L32            7 S L30 AND L26
L33            0 S L31 AND L26
L34            9 S L29,L32
L35           42 S L26 AND ?LATEX?
L36           37 S L26 AND ?RUBBER?
L37            7 S L26 AND ?ELASTOM?
                E LATEX/CT
                E E3+ALL
L38         6573 S E4+NT
                E E10+ALL
L39        14600 S E6+OLD,NT
L40            4 S L26 AND L38,L39

     FILE 'REGISTRY' ENTERED AT 09:53:32 ON 05 AUG 2005
L41             STR L18
L42           50 S L41 SAM SUB=L15
L43         2298 S L41 FUL SUB=L15

     FILE 'HCAPLUS' ENTERED AT 09:55:22 ON 05 AUG 2005
L44            1 S L34 AND L35-L37,L40
L45            9 S L34,L44

     FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005

=> d scan l20

L20  18 ANSWERS   REGISTRY  COPYRIGHT 2005 ACS on STN
IN   Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-
     [[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI)
MF   C22 H30 N4 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-(acetylamino)-2,6-dimethylphenyl]-2-(diethylamino)- (9CI)
MF C16 H25 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-
[[(phenylamino)carbonyl]amino]phenyl]- (9CI)
MF C21 H28 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-[2-(2-methoxyethoxy)ethoxy]- (9CI)
MF C21 H35 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, homopolymer (9CI)
MF (C17 H25 N3 O2)x
CI PMS

CM 1



L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]phenyl]- (9CI)
MF C22 H27 F3 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Tetradecanamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-(9CI)
MF C28 H49 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-3-(trifluoromethyl)- (9CI)
MF C22 H26 F3 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-(2-methoxyethoxy)- (9CI)
MF C19 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Pyrrol-1-yloxy, 3-[[[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]amino]carbonyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI)
MF C23 H35 N4 O3



L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[(1S)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI)
MF C23 H32 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2,5,8,11-Tetraoxatetradecan-14-amide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
MF C24 H41 N3 O6

PAGE 1-A



PAGE 1-B

—CH_2—NEt_2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 9-Tetradecenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, (9Z)- (9CI)
MF C28 H47 N3 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Hexanamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
MF C20 H33 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 4-chloro-N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
MF C21 H26 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[(1R)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI)
MF C23 H32 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-methoxy- (9CI)
MF C17 H27 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
MF C17 H25 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d ide can l30

L30 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 137-58-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2',6'-Acetoxylidide, 2-(diethylamino)- (8CI)
OTHER NAMES:
CN α-Diethylamino-2,6-acetoxylidide
CN 2-(Diethylamino)-2',6'-acetoxylidide
CN 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
CN Anbesol
CN Anestacon
CN Cuivasil
CN Dalcaine
CN Duncaine
CN ELA-Max
CN Esracaine
CN Isicaina
CN Isicaine
CN Jetocaine
CN Leostesin
CN Lida-Mantle
CN Lidocadren
CN **Lidocaine**
CN Lidoderm
CN Lignocaine
CN LMX
CN Maricaine
CN Medicaine
CN NSC 40030
CN Penles
CN Remicaine
CN Rucaina
CN Solarcaine
CN Solcain
CN Xilina
CN Xycaine
CN Xylestesin
CN Xyline
CN Xylocain

CN Xylocaine
CN Xylocitin
FS 3D CONCORD
DR 8059-42-5, 8059-66-3, 91484-71-8
MF C14 H22 N2 O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PIRA, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8056 REFERENCES IN FILE CA (1907 TO DATE)
93 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8068 REFERENCES IN FILE CAPLUS (1907 TO DATE)
31 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:125378

REFERENCE 2: 143:120573

REFERENCE 3: 143:120552

REFERENCE 4: 143:120541

REFERENCE 5: 143:120528

REFERENCE 6: 143:120253

REFERENCE 7: 143:115675

REFERENCE 8: 143:110722

REFERENCE 9: 143:110715

REFERENCE 10: 143:109819

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:56:53 ON 05 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 5 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 4 Aug 2005 (20050804/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l45 all hitstr tot

L45 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:259820 HCAPLUS
DN 142:336135
ED Entered STN: 25 Mar 2005
TI Preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
IN Baker, William R.; Stasiak, Marcin; Macleod, David
PA Corus Pharma, USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025498	A2	20050324	WO 2004-US28063	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-501137P	P	20030908		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005025498	ICM	A61K
WO 2005025498	ECLA	A61K009/00M20B

OS MARPAT 142:336135

GI



I

AB Title compds. [I; X, Y = NH, O, SO2, CO; n = 1-5; W, Z = H, NH, NR, O, CH2; R = alkyl, (substituted) alkenyl; when Z = H, then R1W is absent and when W is absent, R1 is bonded directly to Z; R6B is absent and when B is absent, R6 is bonded directly to A; R1, R6 = H, alkylheterocyclyl, (substituted) alkylaryl, biaryl, aralkyl, alkoxy, alkoxyalkyl, alkyl, alkenyl, alkoxyaryl, alkylaryl, alkyl; R2, R3 = H, Me; R4, R5 = H, alkyl; R4R5 = atoms to form a (substituted) 2-10 membered ring], were prepared Thus, N-(3-amino-2,6-dimethylphenyl)-2-[1,4']-bipiperidin-1'-ylacetamide (preparation given) was stirred with 6-(4-phenylbutoxy)hexanal and NaBH(OAc)3 in CH2Cl2 at 0-5° to give 2-[1,4']bipiperidin-1'-yl-N-[2,6-dimethyl-3-[6-(4-phenylbutoxy)hexylamino]phenyl]acetamide. The latter inhibited eosinophil survival with IC50 = 5 μM.

ST acetanilide benzamide prepn asthma pulmonary inflammation treatment; eosinophil apoptosis mediator benzamide acetanilide prepn

IT Drug delivery systems
(aerosols; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT Eosinophil
(apoptosis mediator; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT Apoptosis
(eosinophil; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT Antiasthmatics
Human
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT Inflammation
(pulmonary inflammation treatment; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT Asthma
(treatment; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT 2210-77-7P 5294-61-1P 7728-40-7P 13327-12-3P 18865-38-8P
21236-54-4P 32795-44-1P 39942-49-9P 39942-50-2P 50295-20-0P
55340-20-0P 75549-83-6P 86523-70-8P 102240-67-5P 106134-54-7P
119053-70-2P 314769-17-0P 331758-55-5P 347196-34-3P 380204-72-8P
484027-66-9P 745789-55-3P 757134-36-4P 848176-38-5P 848441-42-9P
848441-43-0P 848441-44-1P 848441-45-2P **848441-46-3P**
848441-47-4P 848441-48-5P **848441-49-6P** 848441-50-9P
848441-51-0P **848441-52-1P** **848441-53-2P**
848441-54-3P 848441-55-4P 848441-56-5P 848441-57-6P
848441-58-7P **848441-59-8P** **848441-60-1P**
848441-61-2P **848441-62-3P** **848441-63-4P**
848441-64-5P **848441-65-6P** 848441-66-7P 848441-67-8P
848441-68-9P 848441-69-0P 848441-70-3P 848441-71-4P 848441-72-5P

848441-73-6P 848441-74-7P 848441-75-8P 848441-76-9P
848441-77-0P 848441-78-1P 848441-79-2P 848441-80-5P
848441-81-6P 848441-82-7P 848441-83-8P 848441-84-9P 848441-85-0P
848441-86-1P 848441-87-2P 848441-88-3P 848441-89-4P 848441-90-7P
848441-91-8P 848441-92-9P 848441-93-0P 848441-94-1P 848441-95-2P
848441-97-4P 848441-98-5P 848442-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT 51-06-9, Procainamide 75-04-7, Ethylamine, reactions 75-36-5, Acetyl chloride 92-54-6, N-Phenylpiperazine 98-88-4, Benzoyl chloride 100-52-7, Benzaldehyde, reactions 101-83-7, Dicyclohexylamine 103-69-5, N-Ethylaniline 103-71-9, Phenyl isocyanate, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, N-Methylpiperazine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 112-64-1, Myristoyl chloride 122-78-1, Phenylacetaldehyde 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions **137-58-6**, **Lidocaine** 142-61-0, Hexanoyl chloride 544-64-9, cis-9-Tetradecenoic acid 614-39-1, Procainamide hydrochloride 618-46-2, 3-Chlorobenzoyl chloride 624-78-2 625-45-6, Methoxyacetic acid 638-29-9, Valeryl chloride 659-28-9, 4-Trifluoromethoxybenzaldehyde 764-85-2, Nonanoyl chloride 768-94-5, Adamantanamine 841-77-0, 1-Benzhydrylpiperazine 1008-91-9, 1-(4-Pyridyl)piperazine 1131-01-7 2051-28-7, Decahydroquinoline 2251-65-2, 3-Trifluoromethylbenzoyl chloride 2759-28-6, N-Benzylpiperazine 3173-56-6, Benzyl isocyanate 3360-41-6, 4-Phenylbutanol 4318-37-0, N-Methylhomopiperazine 4897-50-1, 1,4'-Bipiperidine 6530-09-2, 3-Aminoquinuclidine dihydrochloride 6874-67-5, Farnesyl bromide 10486-19-8, Tridecanal 13754-38-6, 1-Benzoylpiperazine 13889-98-0, 1-Acetylpiperazine 14002-51-8, 4-Phenylbenzoyl chloride 14649-03-7, (S)-α-Methylbenzyl isocyanate 16024-56-9 16024-58-1 18328-11-5, 4-Phenylbutyraldehyde 21655-48-1, cis-2,6-Dimethylpiperazine 25054-53-9, 3,4-Methylenedioxybenzoyl chloride 27578-60-5, N-(2-Aminoethyl)piperidine 32231-06-4 33375-06-3 34803-66-2 35037-73-1, 4-Trifluoromethoxyphenyl isocyanate 36823-88-8, 4-Trifluoromethoxybenzoyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine 50606-96-7, 4-Heptylbenzoyl chloride 55579-01-6 67319-28-2, 2,5,8,11-Tetraoxatetradecanoic acid 67980-77-2, 1-(3-Pyridyl)piperazine 97664-54-5 112275-50-0, N-tert-Butoxycarbonylhomopiperazine 116258-17-4 287952-09-4 308103-51-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT 38870-89-2P, Methoxyacetyl chloride 848442-01-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT **848441-46-3P 848441-49-6P 848441-51-0P**
848441-52-1P 848441-53-2P 848441-54-3P
848441-58-7P 848441-59-8P 848441-60-1P
848441-61-2P 848441-62-3P 848441-63-4P
848441-65-6P 848441-77-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

RN 848441-46-3 HCAPLUS
CN Tetradecanamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 848441-49-6 HCAPLUS
CN 2,5,8,11-Tetraoxatetradecan-14-amide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 848441-51-0 HCAPLUS
CN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 848441-52-1 HCAPLUS
CN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-[2-(2-methoxyethoxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 848441-53-2 HCAPLUS
CN Acetamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 848441-54-3 HCAPLUS
CN Hexanamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 848441-58-7 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848441-59-8 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848441-60-1 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[(1S)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 848441-61-2 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[(1R)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 848441-62-3 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[(phenylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848441-63-4 HCAPLUS
CN Benzamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 848441-65-6 HCAPLUS
CN 9-Tetradecenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, (9Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 848441-77-0 HCAPLUS
CN 1H-1,4-Diazepine-1-acetamide, N-[2,6-dimethyl-3-[(1-oxotetradecyl)amino]phenyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



IT **137-58-6, Lidocaine**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



L45 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:590987 HCAPLUS
DN 111:190987
ED Entered STN: 25 Nov 1989
TI Agglutination assay
IN Gibbons, Ian
PA Biotrack, Inc., USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM G01N033-546
ICS G01N033-555; G01N033-563
INCL 436512000
CC 9-2 (Biochemical Methods)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4829011	A	19890509	US 1987-90027	19870827
PRAI US 1987-90027		19870827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4829011	ICM	G01N033-546
	ICS	G01N033-555; G01N033-563
	INCL	436512000
US 4829011	NCL	436/512.000; 436/520.000; 436/533.000; 436/534.000; 436/805.000

AB A method of detecting the presence or amount of an analyte in a sample comprises forming a reaction medium containing (1) a sample; (2) particles having a binding pair member bound to their surfaces; and (3) a monovalent complementary partner to the binding pair member to which is attached an analyte mimic or analyte binding partner; and detecting the presence of agglutination of the particles in the reaction medium. In some embodiments a polyvalent receptor capable of binding both with the analyte and analyte mimic or with a 2nd binding site on the analyte is also introduced into the reaction medium. The invention is particularly useful for detecting the presence of analytes in whole blood, since red blood cells can act as the particles with the normal surface antigen of the red blood cells being used in the assay as the binding pair member. **Lidocaine** was determined in anticoagulated blood by agglutination assay using **lidocaine** conjugated to the Fab fragment of rabbit anti-human red blood cell antiserum (preparation given) and goat IgG to **lidocaine.** Agglutination was detected in a blank Protime capillary flow cartridge by passing light from a germanium arsenide semiconductor laser through the cartridge. Decreasing **lidocaine** concentration resulted in an increase in agglutination.

ST agglutination assay; **lidocaine** agglutination assay blood
IT **Latex**
(binding pair member bound to, agglutination reagent containing)
IT Particles
(binding pair member bound to, agglutination test reagent containing)
IT Blood analysis
(by agglutination assay, reagents for)
IT Receptors
RL: ANST (Analytical study)
(for analyte and analyte mimic, agglutination reagent containing)
IT Agglutination
(in anal., reagents for)
IT Erythrocyte
(surface antigen of, analyte or analyte mimic conjugate with antibody fragment to, for agglutination assay)
IT Antibodies
RL: ANST (Analytical study)
(to erythrocyte surface antigen, conjugates with analyte or analyte mimic, agglutination reagent containing)
IT Immunochemical analysis
(agglutination test, reagents for)
IT Antigens
RL: ANST (Analytical study)
(surface, of erythrocyte, antibody fragment to, analyte or analyte mimic conjugate with, for agglutination assay)
IT **137-58-6**, **Lidocaine**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood, by agglutination assay)
IT **67083-26-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of **lidocaine** conjugate with Fab fragment of rabbit anti-human erythrocyte antiserum)
IT **137-58-6**, **Lidocaine**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood, by agglutination assay)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **67083-26-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of **lidocaine** conjugate with Fab fragment of rabbit anti-human erythrocyte antiserum)
RN 67083-26-5 HCAPLUS
CN Butanoic acid, 4-[[4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L45 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:161422 HCAPLUS
DN 104:161422
ED Entered STN: 17 May 1986
TI Homogeneous ferrocene-mediated amperometric immunoassay
AU Di Gleria, Katalin; Green, Monika J.; Hill, H. Allen O.; McNeil, Calum J.
CS Inorg. Chem. Lab., Univ. Oxford, Oxford, OX1 3QR, UK
SO Analytical Chemistry (1986), 58(6), 1203-5
CODEN: ANCHAM; ISSN: 0003-2700
DT Journal
LA English
CC 1-1 (Pharmacology)
Section cross-reference(s): 9, 15
AB An amperometric immunoelectrode based on the ferrocene-mediated oxidation of glucose by glucose oxidase is described. An antigen-ferricinium ion complex was shown to act as an electron acceptor for glucose oxidase. The catalytic current produced in the enzymic oxidation of glucose was specifically inhibited upon binding the antigen-ferrocene complex with antibody. The inhibition could be reversed upon addition of free antigen. Thus, a homogeneous, competitive immunoassay was devised. **Lidocaine** [**137-58-6**] was chosen as the antigen. The assay time was 15 min, with a relative standard deviation of 3-6%.
ST ferrocene amperometric immunoassay **lidocaine** blood
IT Pharmaceutical analysis
(ferrocene-mediated homogeneous amperometric immunoassay for)
IT Immunochemical analysis
(amperometric immunoassay, ferrocene-mediated homogeneous, in pharmaceutical anal.)
IT 100205-71-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with **aminolidocaine**)
IT 27951-88-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with methylferrocene carboxylic acid chloride)
IT **137-58-6**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood plasma by homogeneous amperometric immunoassay)
IT 102-54-5D, drug conjugates
RL: BIOL (Biological study)
(for drug detns. by homogeneous amperometric immunoassays)
IT **100205-70-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use in **lidocaine** determination in blood plasma by homogeneous amperometric immunoassay)
IT **137-58-6**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood plasma by homogeneous amperometric immunoassay)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **100205-70-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use in **lidocaine** determination in blood plasma by homogeneous amperometric immunoassay)
RN 100205-70-7 HCAPLUS
CN Ferrocene, 1-[[[4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]carbonyl]-1',3-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L45 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:481178 HCAPLUS
DN 103:81178
ED Entered STN: 22 Sep 1985
TI Application of spin labeling to drug assays. IV. Spin- and radiolabeled **lidocaine**
AU Yost, Yul; Holtzman, Jordan L.
CS Res. Med. Serv., Veterans Adm. Med. Cent., Minneapolis, MN, 55417, USA
SO Organic Preparations and Procedures International (1985), 17(4-5), 239-49
CODEN: OPPIAK; ISSN: 0030-4948
DT Journal
LA English
CC 1-1 (Pharmacology)
Section cross-reference(s): 25, 27
GI



II

AB Several spin-labeled derivs. of **lidocaine** (I) where the labels were linked to the glycine such as 2,2,6,6-tetramethyl-4-oxopiperidin-1-oxyl I derivative (II) [97729-44-7] or the xylidine moiety of I via a CO or NH2 group were prepared for use in determining free (non protein-bound) levels of
I [**137-58-6**] in blood. To conduct competitive binding studies of spin-labeled I with proteins, radiolabeled I was also prepared
ST **lidocaine** spin label prepn; serum protein binding
lidocaine spin label
IT Blood analysis
(**lidocaine** determination in, spin labeling in evaluation of free and

protein-bound drug in relation to)
IT Proteins
RL: BIOL (Biological study)
(of blood serum, **lidocaine** binding by, spin-labeling technique in determination of)
IT Spin labels
(of **lidocaine**, for **lidocaine** free and protein-bound fraction determination in blood)
IT **137-58-6**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood, free and protein-bound drug in relation to)
IT 75-03-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(ethylation by, of tetramethylpyrrolidinaminoxyl derivative)
IT 1131-01-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)
IT 97729-34-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)
IT 97729-37-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ethylation of)
IT 18865-38-8P 97729-42-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ethylation with carbon-14 labeled Et bromide)
IT 97729-35-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with aminotetramethylpiperidineoxyl)
IT 50666-75-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with spin labels)
IT 39942-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with tetramethylpyrrolineoxylcarboxylic anhydride)
IT 39942-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
IT 57631-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reaction of)
IT 4919-40-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-chloroacetylation of)
IT 603-71-4P 97729-41-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **137-58-6DP**, spin-labeled derivs. 97729-36-7P 97729-38-9P 97729-39-0P 97729-40-3P 97729-43-6P 97729-44-7P **97741-61-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for **lidocaine** free and protein-bound fraction determination in blood)

IT 13810-30-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (aminodimethylphenyl)diethylaminoacetamide)
IT 14691-88-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (chloroacetamido)dimethylbenzoyl chloride)
IT 34272-83-8 42585-33-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (dimethylphenyl)iodoacetamide)
IT 25713-24-0 27048-01-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with diethylamine)
IT 31084-42-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with ethylamino(dimethylphenyl)acetamide)
IT 3095-38-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
IT 109-89-7, biological studies
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution reaction of, with chloro(dimethylnitrophenyl)acetamide)
IT **137-58-6**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood, free and protein-bound drug in relation to)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **137-58-6DP**, spin-labeled derivs. **97741-61-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for **lidocaine** free and protein-bound fraction
determination in blood)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 97741-61-2 HCAPLUS
CN 1H-Pyrrol-1-yloxy, 3-[[[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]amino]carbonyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)



L45 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:444227 HCAPLUS
DN 89:44227
ED Entered STN: 12 May 1984
TI **Lidocaine** antigens and antibodies
IN Singh, Prithipal
PA Syva Co., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
IC C07G007-00
INCL 195063000
CC 34-2 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 25, 15, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4069105	A	19780117	US 1977-775658	19770303
	DE 2805962	A1	19780907	DE 1978-2805962	19780213
	DE 2805962	C2	19871223		
	JP 53108904	A2	19780922	JP 1978-19593	19780222
	JP 02036599	B4	19900817		
	AU 7833768	A1	19790906	AU 1978-33768	19780302
	AU 513665	B2	19801211		
	JP 01020451	A2	19890124	JP 1987-290422	19871117
	JP 02043144	B4	19900927		
	JP 03002199	A2	19910108	JP 1990-88991	19900403
PRAI	US 1977-775658	A	19770303		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4069105	IC	C07G007-00
	INCL	195063000
US 4069105	NCL	530/363.000; 435/007.900; 435/188.000; 435/190.000; 435/961.000; 435/964.000; 436/517.000; 436/536.000; 436/543.000; 436/547.000; 436/816.000; 525/420.000; 528/328.000; 530/389.800; 530/391.900; 530/403.000;

530/405.000; 530/406.000; 530/409.000; 530/806.000

GI



AB **Lidocaine**-antigen conjugates I [R, R1 = C1-4 alkyl; R2 = H, Me; R1R2 = 6-membered ring with C and N; R3 = R4 = Me, R3 = H, R4 = Me, R3 = Me, R4 = H; Z = linking group; Q = poly(amino acid) (mol. weight at least 5,000), antigen, enzyme; n = 1 to number of available NH2 groups of Q] were prepared as agents for the preparation of antibodies which can be used in competitive protein binding assays. Thus, aniline II (R5 = H, R6 = NO2) was N-acylated with ClCH2COCl to give 73% anilide which was aminated with Et2NH2 to give 80% II (R5 = Et2NCH2CO, R6 = NO2) which was hydrogenated over Adams' catalyst to give II (R5 = Et2NCH2CO, R6 = NH2). The latter was treated with succinic anhydride to give II (R5 = Et2NCH2CO, R6 = NHCOCH2CH2CO2H) (III) which was conjugated to bovine serum albumin (BSA) by iso-Bu chloroformate to give III-BSA conjugate.

ST **lidocaine** antigen conjugate prepn antibody; glycine anilide antigen conjugate

IT Albumins, blood serum
RL: PRP (Properties)
(conjugation of, with **lidocaine** derivative)

IT Antibodies
RL: FORM (Formation, nonpreparative)
(formation of, to **lidocaine**-antigens conjugates)

IT Enzymes
(**lidocaine** conjugates)

IT Albumins, blood serum
Antigens
(**lidocaine** conjugates, preparation of)

IT Peptides, preparation
(poly-, **lidocaine** conjugates)

IT Globulins
RL: PRP (Properties)
(γ-, conjugation of, with **lidocaine** derivative)

IT Globulins
(γ-, **lidocaine** conjugates, preparation of)

IT 98-59-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of dimethylaniline)

IT 87-62-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, by tosyl chloride)

IT **67083-29-8**
RL: PRP (Properties)
(conjugation of, with glucose phosphate dehydrogenase)

IT 9001-40-5
RL: PRP (Properties)
(conjugation of, with **lidocaine** derivative)

IT **67083-26-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation and conjugation of, with proteins)
IT **67083-25-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with γ-globulin)
IT 67083-24-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
IT 67083-22-1P 67083-27-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
IT 4703-15-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)
IT 16947-63-0P 67083-28-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with chloroacetyl chloride)
IT 57631-94-4P 67083-23-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with diethylamine)
IT 27951-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with nitrophenyl chloroformate)
IT 9001-40-5DP, **lidocaine** conjugate 39942-49-9P
67083-25-4DP, γ-globulin conjugate **67083-26-5DP**, protein conjugates
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 79-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aniline derivative)
IT 109-89-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetanilide derivative)
IT 7693-46-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with **lidocaine** derivative)
IT **67083-29-8**
RL: PRP (Properties)
(conjugation of, with glucose phosphate dehydrogenase)
RN 67083-29-8 HCAPLUS
CN Butanoic acid, 4-[[4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



IT **67083-26-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with proteins)
RN 67083-26-5 HCAPLUS
CN Butanoic acid, 4-[[4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



IT **67083-25-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with γ-globulin)
RN 67083-25-4 HCAPLUS
CN Carbamic acid, [4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



IT **67083-25-4DP**, γ-globulin conjugate **67083-26-5DP**, protein conjugates
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 67083-25-4 HCAPLUS
CN Carbamic acid, [4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 67083-26-5 HCAPLUS
CN Butanoic acid, 4-[[4-[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L45 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1959:125066 HCAPLUS
DN 53:125066
OREF 53:22506d-e
ED Entered STN: 22 Apr 2001
TI Relations between chemical constitution and pharmacological activity in various types of new local anesthetics. V. Aminoacylamides and anilides; substitution in the acylated amino group
AU Koelzer, Paul P.; Wehr, Klaus H.
CS Med. Akad., Dusseldorf, Germany
SO Arzneimittel-Forschung (1958), 8, 609-15
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA Unavailable
CC 11H (Biological Chemistry: Pharmacology)
AB cf. ibid. 544. In compds. of the general formula ArN(R)OCR'N<, substitution of R by alkyl groups causes loss of local anesthetic activity and increased toxicity. Replacement of phenyl by other aryl groups or alkyl chains also results in reduction of anesthetic activity. Substitution of the terminal amino group by piperazine derivs. results in active compds. of pantocaine-like character.
IT Amides
(anesthetic action of)
IT Anilides
(anesthetics)
IT Anesthetics
Anesthetics
(local, action of)
IT 4-Piperidinecarboxy-2',6'-xylidide, 1-methyl-
(as local anesthetic)
IT **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino-
(anesthetic action of)
IT 3213-14-7, o-Acetotoluidide, 2-diethylamino- 108951-43-5, 1-Pyrrolidineaceto-o-toluidide, 6'-chloro-
(as anesthetic)

IT 2210-77-7, 1-Pyrrolidineaceto-2',6'-xylidide 3213-12-5, o-Acetotoluidide, 6'-chloro-2-diethylamino- 3847-42-5, 1-Pyrrolidineacetamide, N-1,2-diphenylethyl- 16417-75-7, Acetamide, 2-diethylamino-N-(2-methyl-1-naphthyl)- 31058-85-2, 2',6'-Acetoxylidide, 2-diethylamino-N-methyl- 37390-27-5, 1-Pyrrolidineacetamide, N-diphenylmethyl- 46726-88-9, 1-Pyrrolidineaceto-o-toluidide 59960-80-4, Acetamide, 2-diethylamino-N-diphenylmethyl- 65446-95-9, Acetanilide, 4'-chloro-2-diethylamino- 70289-10-0, o-Acetotoluidide, 6'-chloro-2-dimethylamino- 74816-25-4, Acetanilide, 4'-chloro-2-diethylamino-N-methyl- 100318-28-3, 1-Pyrrolidineacetamide, N-(4-methyl-3-pyridyl)- 100861-57-2, o-Acetotoluidide, 2-diethylamino-N-methyl- 101452-62-4, 1-Pyrrolidineacetamide, N-1,5-dimethylhexyl-N-methyl- 101589-88-2, 4-Picoline, 2-(2-diethylaminoacetamido)- 101592-98-7, 1-Pyrrolidineacetamide, N-undecyl- 101777-75-7, 1-Pyrrolidineacetamide, 2,5-dimethyl-N-(4-methyl-3-pyridyl)- 101784-86-5, Acetamide, 2-diethylamino-N,N-diphenyl- 102310-07-6, Benzoic acid, p-(N-butyl-2-propylaminoacetamido)-, butyl ester 102945-78-8, Benzoic acid, p-(N-butyl-2-piperidinoacetamido)-, butyl ester 105474-63-3, o-Acetotoluidide, 6'-chloro-2-dimethylamino-N-methyl- 106841-23-0, 1-Pyrrolidineacetamide, N-1,5-dimethyl-4-hexenyl- 108849-33-8, o-Acetotoluidide, 6'-chloro-2-diethylamino-N-methyl- 109476-32-6, 1-Pyrrolidineaceto-o-toluidide, N-acetyl-6'-chloro- 109615-38-5, o-Acetotoluidide, N-benzyl-6'-chloro-2-diethylamino- 110060-58-7, 1-Pyrrolidineaceto-o-toluidide, 6'-chloro-N-methyl- 111474-07-8, 1-Pyrrolidineaceto-2',6'-xylidide, N-butyl-α-methyl- **113454-93-6**, 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-phenylene)bis- 114203-10-0, 1-Pyrrolidineaceto-2',6'-xylidide, α-phenyl- 119113-48-3, 2',6'-Propionoxylidide, N-butyl-2-butylamino- 130987-85-8, Acetamide, 2-diethylamino-N-(1-methyloctyl)- 131217-14-6, 1-Pyrrolidineacetamide, N-1,5-dimethyl-4-hexenyl-N-methyl- 131590-07-3, o-Acetotoluidide, 2-diethylamino-N-ethyl- 132674-83-0, 2',6'-Acetoxylidide, N-butyl-2-ethylamino- 132752-39-7, 1-Pyrrolidineaceto-o-toluidide, N-ethyl- 132887-74-2, 1-Pyrrolidineaceto-2',6'-xylidide, N-methyl-
(as local anesthetic)

IT **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino-
(anesthetic action of)

RN 137-58-6 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **113454-93-6**, 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-phenylene)bis-
(as local anesthetic)

RN 113454-93-6 HCAPLUS

CN 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-phenylene)bis- (6CI) (CA INDEX NAME)



L45 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1959:91300 HCAPLUS
DN 53:91300
OREF 53:16472i,16473a
ED Entered STN: 22 Apr 2001
TI Electrophoretic behavior of some local anesthetics
AU Baruffini, A.
CS Univ. Pavia, Italy
SO Farmaco, Edizione Pratica (1958), 13, 466-71
CODEN: FRPPAO; ISSN: 0430-0912
DT Journal
LA Unavailable
CC 17 (Pharmaceuticals, Cosmetics, and Perfumes)
AB The anesthetics tested were benzocaine, procaine, butocaine, tutocaine, orthocaine, xylocaine, stovaine, cocaine, ambrostasine, cornecaine, and nupercaine. Conditions were 7 v./cm. for 3 hrs. on Schleicher and Schull paper 2043 B. The electrolyte was H3PO3, H3BO3, AcOH, and NaOH buffer which permits pH values 2-12 at constant ionic strength. The concentration of the anesthetics was 1%. Aromatic amines were sprayed with 1% NaNO2 or 1% α-naphthol and 17% NH3. For aliphatic amines, Dragendorff's reagent was used. All compds. migrated sufficiently for analytical purposes. The rate of migration depended on the moles of the anesthetic and on the pH.
IT 1,2-Propanediol, 3-dimethylamino-, p-propylaminobenzoate
Ambrostasine
Orthoform or Orthoform-new
(electrophoresis of)
IT 50-36-2, Cocaine 59-46-1, Procaine 85-79-0, Dibucaine 94-09-7, Benzocaine **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino- 149-16-6, Butacaine 644-26-8, Amylocaine 891-33-8, Tutocaine 3686-68-8, Benzoic acid, p-propylamino-, 3-dimethylamino-2-hydroxypropyl ester **23724-96-1**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)
IT **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino- **23724-96-1**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 23724-96-1 HCAPLUS
CN Acetamide, N,N'-1,2-phenylenebis[2-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)



L45 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1959:91299 HCAPLUS
DN 53:91299
OREF 53:16472g-i
ED Entered STN: 22 Apr 2001
TI Separation of some tropaalkaloids by countercurrent distribution
AU Siesto, A. J.
CS Univ. Rome
SO Farmaco, Edizione Pratica (1958), 13, 445-58
CODEN: FRPPAO; ISSN: 0430-0912
DT Journal
LA Unavailable
CC 17 (Pharmaceuticals, Cosmetics, and Perfumes)
AB The distribution of hyoscyamine, hyoscine, and atropine in countercurrent distribution was studied in artificial mixts. and in natural plant exts. Partition coeffs. in the system CHCl3-phosphate buffer 0.5M (vols. 1:1), partition curves, and the ratios of log 10 K to the pH of the 3 alkaloids has been determined Hyoscine seps. from hyoscyamine and atropine, but atropine does not sep. from hyoscyamine. The latter, after prolonged contact with the buffer solution, tends to be transformed by racemization into atropine. This prevents a separation which, theoretically, would be possible. Distribution curves were prepared with mixts. of the alkaloids of Atropa belladonna, Hyozcyamus niger, and Scopolia carniolica. The presence of some minor alkaloids was observed.
IT Hyoscyamus niger
(alkaloid separation from)
IT Belladonna and(or) Atropa
Scopolia carniolica
(alkaloids of, separation of)
IT Alkaloids
(of belladonna, Hyoscyamus and Scopolia, separation of)
IT 1,2-Propanediol, 3-dimethylamino-, p-propylaminobenzoate
Orthoform or Orthoform-new
(electrophoresis of)
IT 85-79-0, Dibucaine **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino- 149-16-6, Butacaine 644-26-8, Amylocaine 3686-68-8, Benzoic acid, p-propylamino-, 3-dimethylamino-2-hydroxypropyl ester **23724-96-1**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)
IT 51-34-3, Scopolamine 51-55-8, Atropine 101-31-5, Hyoscyamine
(separation of)
IT **137-58-6**, 2',6'-Acetoxylidide, 2-diethylamino- **23724-96-1**
, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)
RN 137-58-6 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 23724-96-1 HCAPLUS
CN Acetamide, N,N'-1,2-phenylenebis[2-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)



L45 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1958:67835 HCAPLUS
DN 52:67835
OREF 52:12211b-e
ED Entered STN: 22 Apr 2001
TI A local anesthetic derived from o-phenylenediamine: N,N'-bis(isobutylaminoacetyl) - o-phenylenediamine
AU Tricerri, S.; Guzzon, V.
CS Ist. sieroterap. Milan. S. Belfanti
SO Farmaco, Edizione Scientifica (1957), 12, 954-9
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA Unavailable
CC 11H (Biological Chemistry: Pharmacology)
AB One mole o-phenylenediamine in 3 vols. AcOH and 2.2 moles ClCH2COCl gives in the presence of NaOAc at room temperature 87% N,N' - bis(chloroacetyl) - o - phenylenediamine, m. 192-4°. Treating it with 5 moles iso-BuNH2 in C6H6, first at room temperature, then by refluxing 8 hrs., filtering, evaporating in vacuo, dissolving in 2 l. H2O containing 2 moles HCl, adjusting the pH to 6.5, decolorizing, and filtering, gave by alkalinization 100% N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine, m. 88-9°; HCl salt m. 264° (MeOH). The acute subcutaneous toxicity of the HCl salt in the mouse was L.D.50 940 mg./kg., in the guinea pig 850 to 1100 mg./kg. Subcutaneous instillation of a 2% solution in rabbits and guinea pigs was seemingly well tolerated. There was no reaction in the rabbit eye. Giving 1 cc. trypan blue intravenously 20 min. after a subcutaneous injection of 0.3 cc. caused a slight blue coloration at the site of injection, indicating a mild irritation. The min. hemolytic concentration was 2%. Doses of 1 mg./kg. caused in the anesthetized rabbit a drop in blood pressure and an insignificant effect on respiration. The drug inhibited the spontaneous movements of

the isolated rabbit intestine and had a slight antihistaminic effect. Infiltration anesthesia in guinea pigs and humans showed a duration of 90 min. average, which was identical with that of **lidocaine.** In conduction anesthesia, the effect lasted longer than that of **lidocaine.**

IT Blood pressure
(-lowering substances, N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine as)

IT Anesthetics
(N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine as local)

IT Intestines
(N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine effect on)

IT 2810-42-6, Acetamide, N,N'-o-phenylenebis[2-chloro- **103267-80-7**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate **107924-26-5**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride
(preparation of)

IT **103267-80-7**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate **107924-26-5**, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride
(preparation of)

RN 103267-80-7 HCAPLUS

CN Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate (6CI) (CA INDEX NAME)

CM 1

CRN 23724-96-1
CMF C18 H30 N4 O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 107924-26-5 HCAPLUS

CN Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

=> => d all hitstr

L47 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:35324 HCAPLUS
DN 84:35324
ED Entered STN: 12 May 1984
TI Polymeric local anesthetic and antiarrhythmic agents
IN Okamoto, Yoshiyuki; Riker, Walter F., Jr.; Udenfriend, Sidney
PA Hoffmann-La Roche, Inc., USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC C07C
INCL 260472000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 25, 35
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3914283	A	19751021	US 1973-423644	19731210
PRAI	US 1973-423644	A	19731210		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 3914283	IC	C07C
	INCL	260472000
US 3914283	NCL	560/049.000; 514/818.000; 514/821.000; 548/524.000; 548/540.000; 564/194.000

AB Polymers comprising repeating units of local anesthetics covalently bonded by an amide linkage to a group derived from a carboxyl of a polymeric acid backbone exhibit local anesthetic and antiarrhythmic activities similar to the parent moiety but with longer duration. Thus, poly(acrylylprocaine) [57635-62-8] was prepared by polymerization of acrylylprocaine [25252-96-4] or reaction of poly(acryloyl chloride) [25189-84-8] with procaine-HCl [51-05-8]. The polymeric local anesthetics exhibited a slower onset and development of toxic effects and a longer duration of these effects than their comparable anesthetics. All of the polymers and their monomers produced a reversible conduction block of the compound action potential in frog sciatic nerve in vitro. Thus, these compds. were indistinguishable from the prototype local anesthetics. Also the polymers administered i.v. to the cat, variably suppressed the development of epinephrine-induced ectopic ventricular beats, again similar to the parent moieties.
ST polymer local anesthetic; antiarrhythmic polymer local anesthetic
IT Heart, disease or disorder

(arrhythmia, local anesthetic polymers for treatment of)
IT Anesthetics
(local, polymers)
IT Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, monohydrochloride, reaction product with polyacryloyl chloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic and local anesthetic with prolonged action)
IT 1131-01-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)
IT 39942-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with acryloyl chloride)
IT 57631-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with diethylamine)
IT 39942-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
IT 25189-84-8P 25252-96-4P **57631-91-1P** 57631-92-2P
57631-93-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 25189-84-8DP, 2-Propenoyl chloride, homopolymer, reaction products with procaine 57635-62-8P **57635-63-9P** 57635-64-0P 57635-65-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic and local anesthetic with prolonged action)
IT 614-39-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with acryloyl chloride)
IT 87-62-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetyl chloride)
IT 109-89-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetylamino(dimethyl)nitrobenzene)
IT 79-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylaniline)
IT 814-68-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with local anesthetics)
IT **57631-91-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57631-91-1 HCAPLUS
CN 2-Propenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-(9CI) (CA INDEX NAME)



IT **57635-63-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic and local anesthetic with prolonged action)
RN 57635-63-9 HCAPLUS
CN 2-Propenamide, N-[3-[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 57631-91-1
CMF C17 H25 N3 O2



=> d his

(FILE 'HCAPLUS' ENTERED AT 09:28:10 ON 05 AUG 2005)
DEL HIS
E CHU V/AU
L1 173 S E3,E6,E26,E32,E33
E TENG Z/AU
L2 22 S E3-E5 OR TENG ZHU?/AU
E LEWISCH S/AU
L3 5 S E4
E EDWARDS R/AU
L4 306 S E3,E20-E22
E EDWARDS RON/AU
L5 4 S E3,E6,E13
L6 510 S L1-L5
L7 0 S L6 AND ?LIDOCAIN?
L8 8 S L6 AND BENZ?/SC,SX
L9 0 S L1 AND L2-L5
L10 0 S L2 AND L3-L5
L11 0 S L3 AND L4,L5
L12 0 S L4 AND L5

```
     FILE 'REGISTRY' ENTERED AT 09:30:46 ON 05 AUG 2005
L13             STR
L14           50 S L13
L15         5958 S L13 FUL
                SAV L15 KUMAR828/A
L16            0 S L15 AND C21H37N5O2
L17            0 S L15 AND C24H41N5O5
L18              STR L13
L19            2 S L18 SAM SUB=L15
L20           18 S L18 FUL SUB=L15
                SAV L20 KUMAR828A/A
L21          332 S L15 AND PMS/CI
L22            0 S L21 AND (LATEX OR STARCH)
L23            1 S STARCH/CN
L24            0 S 9005-25-8/CRN AND L15
L25           16 S L15 AND OC2/ES

     FILE 'HCAPLUS' ENTERED AT 09:47:08 ON 05 AUG 2005
L26         2747 S L15
L27            0 S L6 AND L26
L28            0 S L26 AND (DADE? OR BEHRING? OR DEUTSCHE BANK?)/PA,CS
L29            6 S L26 AND ?LIDOCAIN?

     FILE 'REGISTRY' ENTERED AT 09:49:05 ON 05 AUG 2005
L30            1 S LIDOCAINE/CN
L31          248 S 137-58-6/CRN

     FILE 'HCAPLUS' ENTERED AT 09:49:28 ON 05 AUG 2005
L32            7 S L30 AND L26
L33            0 S L31 AND L26
L34            9 S L29,L32
L35           42 S L26 AND ?LATEX?
L36           37 S L26 AND ?RUBBER?
L37            7 S L26 AND ?ELASTOM?
                E LATEX/CT
                E E3+ALL
L38         6573 S E4+NT
                E E10+ALL
L39        14600 S E6+OLD,NT
L40            4 S L26 AND L38,L39

     FILE 'REGISTRY' ENTERED AT 09:53:32 ON 05 AUG 2005
L41             STR L18
L42           50 S L41 SAM SUB=L15
L43         2298 S L41 FUL SUB=L15

     FILE 'HCAPLUS' ENTERED AT 09:55:22 ON 05 AUG 2005
L44            1 S L34 AND L35-L37,L40
L45            9 S L34,L44

     FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005

     FILE 'HCAPLUS' ENTERED AT 09:56:53 ON 05 AUG 2005
L46            3 S L20
L47            1 S L46 NOT L45

=>
```